Skip to main content

Biovie Inc.

BIVIW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001580149

In the last 90 days, Biovie Inc. insiders filed 5 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.07M in total; no superinvestor holds it.

Other share classesBIVI

Key figures

Market capClose on Nov 17, 2026
$10.7M
Insider buysLast 90 days, $52.0K in total
5
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
8
13F valueReported value at the end of Q2 2026
$1.07M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2026
–
No comparable prior period
Net income, FY2026
-$22.1M
No comparable prior period
Free cash flow, FY2026
–
No comparable prior period
Revenue, Q1 FY2027
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
50.4K
Shares sold short
Change
+20.4K
+67.7% vs. previous
Days to cover
2.24
At average daily volume

Superinvestors holding BIVIW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIVIW at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Biovie Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)4:30 PM ETNov 133 daysDo Cuong VPresident & CEOPPurchase+2.50K$1.16+$2.91K+15.5%18.6K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayPalumbo Joseph MChief Medical OfficerPPurchase+4.84K$2.16+$10.5K+406.0%6.04K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayChappell Amy SuzonDirectorPPurchase+727$2.16+$1.57KNew position727 after
Aug 28, 2026 (view filing)8:58 PM ETAug 28Same dayKim Joanne WendyChief Financial OfficerPPurchase+2.50K$2.18+$5.45K+265.7%3.44K after
Aug 28, 2026 (view filing)8:57 PM ETAug 271 dayDo Cuong VPresident & CEOPPurchase+15.2K$2.08+$31.6K+1,677.0%16.1K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K––+100.2%9.99K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K–––5.05K afterDerivative
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+10.0K––+2.3%435.9K after
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+5.00K–––5.00K afterDerivative
Dec 6, 2023 (view filing)Dec 15 daysLateGorlin SteveDirectorSSale−75.7K$1.69−$127.9K−62.0%46.4K after

Top 10 13F holders, Q2 2026

See all 8 holders

The largest institutional positions in Biovie Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding BIVIW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Diametric Capital, LP750,000$337.5K0.04%00.0%Unchanged
Warberg Asset Management LLC613,426$276.0K0.08%+156,797+34.3%Added
Armistice Capital, LLC500,000$225.0K0.01%00.0%Unchanged
Prelude Capital Management, LLC186,621$84.0K0.01%00.0%Unchanged
MYDA Advisors LLC159,800$71.9K0.02%−9,113−5.4%Reduced
Heights Capital Management, Inc90,000$40.5K0.01%00.0%Unchanged
Armstrong Advisory Group, Inc65,900$29.7K0.00%00.0%Unchanged
Two Sigma Securities, LLC13,884$6.25K0.00%+2,750+24.7%Added